Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

被引：38

作者：

Tuccori, Marco ^{[1
]}

Focosi, Daniele ^{[2
]}

Blandizzi, Corrado ^{[1
,5
]}

Pelosini, Matteo ^{[2
]}

Montagnani, Sabrina ^{[1
,5
]}

Maggi, Fabrizio ^{[3
,4
]}

Pistello, Mauro ^{[3
,4
]}

Antonioli, Luca ^{[1
]}

Fornai, Matteo ^{[1
]}

Pepe, Pasquale ^{[6
]}

Rossi, Giuseppe ^{[6
]}

Petrini, Mario ^{[2
]}

机构：

[1] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy

[2] Univ Pisa, Div Haematol, Dept Oncol Transplantat & New Technol Med, Pisa, Italy

[3] Univ Pisa, Virol Sect, Pisa, Italy

[4] Univ Pisa, Retrovirus Ctr, Dept Expt Pathol, Pisa, Italy

[5] Tuscan Reg Ctr Pharmacovigilance, Pisa, Italy

[6] CNR, Unit Epidemiol & Biostat, Inst Clin Physiol, Pisa, Italy

来源：

ONCOLOGIST | 2010年 / 15卷 / 11期

关键词：

Rituximab; Progressive multifocal leukoencephalopathy; JCV; Monoclonal antibody; Non-Hodgkin's lymphoma; ADVERSE DRUG EVENTS; NATALIZUMAB; EFALIZUMAB; THERAPY; PROJECT; DISEASE; PML;

D O I：

10.1634/theoncologist.2010-0098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1-4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. The Oncologist 2010;15:1214-1219

引用

页码：1214 / 1219

页数：6

共 50 条

[31] Non-Hodgkin's lymphomas
Theodossiou, C
Schwarzenberger, P
CLINICAL OBSTETRICS AND GYNECOLOGY, 2002, 45 (03): : 820 - 829
[32] Non-Hodgkin’s Lymphomas
不详
Bone Marrow Transplantation, 1999, 23 (Suppl 1) : S155 - S163
[33] Non-Hodgkin's Lymphomas
Jardin, Fabrice
Tilly, Herve
HEMATOLOGIE, 2006, 12 : 17 - 24
[34] How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas
Mohammed, Raihan
Milne, Artemis
Kayani, Kayani
Ojha, Utkarsh
JOURNAL OF BLOOD MEDICINE, 2019, 10 : 71 - 84
[35] Recent Advances in the Treatment of Non-Hodgkin's Lymphomas
Abramson, Jeremy S.
Zelenetz, Andrew D.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (5.5): : 671 - 675
[36] Cladribine for the treatment of indolent non-Hodgkin's lymphomas
Hoffman, MA
SEMINARS IN HEMATOLOGY, 1996, 33 (01) : 40 - 44
[37] Treatment and prognosis of orbital non-Hodgkin's lymphomas
Baldini, L
Blini, M
Fossati, V
Colombi, M
Neri, A
Bertoni, F
LaTargia, ML
Villa, S
Bertoni, G
Maiolo, AT
BLOOD, 1996, 88 (10) : 2259 - 2259
[38] Rituximab combinations in the treatment of non-Hodgkin's lymphoma
Leonard, John P.
CANCER INVESTIGATION, 2007, 25 : 43 - 44
[39] Treatment of non-Hodgkin's lymphomas in elderly patients
Bordonaro, R
Fratino, L
Serraino, D
CLINICAL LYMPHOMA, 2004, 5 (01): : 37 - 44
[40] BAD RISK NON-HODGKIN LYMPHOMAS
HORWICH, A
PECKHAM, M
SEMINARS IN HEMATOLOGY, 1983, 20 (01) : 35 - 56

← 1 2 3 4 5 →